Neuronetics (STIM)
(Delayed Data from NSDQ)
$0.78 USD
0.00 (0.00%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $0.78 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.78 USD
0.00 (0.00%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $0.78 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
Zacks News
Neuronetics' (STIM) Latest Deal to Aid Mental Health Treatments
by Harshit Gupta
Neuronetics (STIM) announces the acquisition of Greenbrook to provide better care to patients suffering from mental health conditions.
Neuronetics (STIM) Inks a New Merger Agreement With Greenbrook
by Zacks Equity Research
Neuronetics (STIM) signs a merger agreement with Greenbrook to acquire all its outstanding shares. The transaction is expected to be closed during the fourth quarter of 2024.
Neuronetics (STIM) Q2 Loss Wider Than Expected, Revenues Fall Y/Y
by Zacks Equity Research
Neuronetics' (STIM) second-quarter 2024 top-line results reflect lower revenues from NeuroStar Advanced Therapy System and Treatment sessions.
Neuronetics (STIM) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Neuronetics (STIM) delivered earnings and revenue surprises of -22.22% and 12.29%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Accelerate Diagnostics (AXDX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 9.09% and 0.47%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Integra LifeSciences (IART) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Integra (IART) delivered earnings and revenue surprises of 1.61% and 1.43%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Neuronetics (STIM) Expands NeuroStar Portfolio With New Launch
by Zacks Equity Research
Neuronetics (STIM) announces the nationwide launch of the Better Me Provider (BMP) program developed in collaboration with TMS medical experts. The BMP program will be part of the company's NeuroStar product line.
Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Neuronetics (STIM) delivered earnings and revenue surprises of 18.18% and 1.85%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Neuronetics' (STIM) FDA-Cleared NeuroStar to Aid in Depression
by Zacks Equity Research
Neuronetics (STIM) announces the FDA's approval of NeuroStar Advanced Therapy, which is likely to aid in the treatment of depression in adolescents by acting as a supplement.
Neuronetics (STIM) Progresses in MRD and TRD With New Deal
by Zacks Equity Research
The collaboration between Neuronetics (STIM) and TCN holds particular significance in the realm of treatment-resistant depression.
Neuronetics (STIM) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Neuronetics (STIM) delivered earnings and revenue surprises of 26.92% and 2.99%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
The Cooper Companies (COO) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
The Cooper Companies (COO) delivered earnings and revenue surprises of 7.59% and 1.80%, respectively, for the quarter ended January 2024. Do the numbers hold clues to what lies ahead for the stock?
OPKO Health (OPK) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
OPKO Health (OPK) delivered earnings and revenue surprises of 0% and 2%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Artivion (AORT) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Artivion (AORT) delivered earnings and revenue surprises of 184.62% and 4.37%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Neuronetics (STIM) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Neuronetics (STIM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Globus Medical (GMED) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Globus Medical (GMED) delivered earnings and revenue surprises of 5% and 3.37%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
LivaNova (LIVN) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
LivaNova (LIVN) delivered earnings and revenue surprises of 34.48% and 10.30%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Abbott (ABT) EPD Sales Gain Traction, Margin Pressure Lingers
by Zacks Equity Research
Abbott (ABT) continues to make good progress in Nutrition, increasing manufacturing production and recovering market share in this business.
LabCorp (LH) Gives Update as Fortrea Spinoff Nears Closure
by Zacks Equity Research
Fortrea is set to comprise Labcorp's (LH) Clinical Development and Commercialization Services businesses.
Illumina (ILMN) Sequencing Arm Grows, Margin Woes Linger
by Zacks Equity Research
Illumina's (ILMN) total sequencing activity on connected high- and mid-throughput instruments are growing strongly.
Charles River (CRL) to Aid INADcure in Plasmid DNA Manufacture
by Zacks Equity Research
Charles River (CRL) collaborates with INADcure Foundation on plasmid DNA manufacturing for developing treatments for INAD patients.
Bruker (BRKR) Launches timsTOF Ultra Mass Spec and VistaScan
by Zacks Equity Research
Bruker (BRKR) introduces the timsTOF Ultra mass spectrometer and VistaScan software for enhanced dia-PASEF 4D-Proteomics at the 71st ASMS meeting.
Quest Diagnostics' (DGX) Contract Wins Aid Amid Volume Woes
by Zacks Equity Research
Quest Diagnostics (DGX) succeeds on contract wins in its reference and professional lab services offerings.
Bruker's (BRKR) Latest Workflows to Aid Applied Markets
by Zacks Equity Research
Bruker (BRKR) introduces Novel EVOQ DART-TQ+ for chromatography-free mass spectrometry for applied markets.
Walgreens Boots (WBA) Gains From New Alliances Amid Macro Woes
by Zacks Equity Research
Continued slowdown in generic introduction has been affecting Walgreens Boots' (WBA) margins.